Santhera Pharmaceuticals is testing anti-cell death compound omigapil in children and teens with merosin-deficient and Ullrich congenital muscular dystrophies

posted on March 26, 2015 - 6:57pm
Santhera Pharmaceuticals continues to recruit participants for a phase 1 trial of omigapil in children and adolescents with the type 1A form of congenital muscular dystrophy (CMD)
posted on March 31, 2011 - 10:19am
QUEST Vol. 18, No. 2
Update (January 25, 2012): This story was updated to reflect the online availability of a CMD Family Guide.